Zikria Dean reported grant involving 50,000 derivative units of Valion Bio, Inc. at $0.00 for $0 on Sep 22, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Interim CEO
Interim CEO
Filed Sep 24, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
50,000Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
50,000Direct
Trade date
Sep 22, 2026Grant
Filed
Sep 24, 2026, 4:46 PM ET2-day reporting delay
Accession
0001683168-26-007398Code A · Transaction 229144
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

VBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 1, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F2: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026. F3: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.